<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01056783</url>
  </required_header>
  <id_info>
    <org_study_id>OC000459/013/09</org_study_id>
    <nct_id>NCT01056783</nct_id>
  </id_info>
  <brief_title>Proof of Concept Study of OC000459 in Eosinophilic Esophagitis</brief_title>
  <official_title>A Randomized, Placebo-controlled, Double-blind, Single-centre Proof-of-concept Study of OC000459 in Adult Patients With Active Eosinophilic Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oxagen Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oxagen Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a randomised, double blind, placebo controlled, parallel group evaluation of the
      effect of OC000459 given orally for eight weeks on active eosinophilic esophagitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of OC000459 on eosinophil load of the esophageal tissue</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of OC000459 on clinical manifestations of EoE</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of OC000459 on endoscopic alterations</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of OC000459 on EoE related blood and tissue biomarkers</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of OC000459 in patients with active EoE</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Eosinophilic Esophagitis</condition>
  <arm_group>
    <arm_group_label>OC000459</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OC000459 100mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OC000459</intervention_name>
    <description>OC000459 100mg, twice daily, tablet</description>
    <arm_group_label>OC000459</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets to match OC000459 tablets, twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously diagnosed and symptomatic isolated eosinophilic esophagitis.

          -  Relevant eosinophil tissue inflammation as demonstrated by a mean eosinophil load &gt;=
             20 eos/hpf in 8 biopsies at the baseline visit.

          -  Able to swallow placebo medication successfully under supervision in the clinic

          -  Free of all medications for EoE (including topical steroids) for at least 2 weeks
             prior to baseline and free of systemic steroids for at least 90 days before screening.
             A proton-pump inhibitor is allowed if required for treatment of secondary acid reflux.

        Exclusion Criteria:

          -  Other causes of esophagitis (GERD, peptic ulceration, infection etc.)

          -  Other causes of eosphagaeal or generalized eosinophilia (i.e. hypereosinophilic
             syndromes, parasitic infection, GERD)

          -  The patient's EoE is dependant on the level of seasonal allergens and the patient's
             participation in the study will occur during the allergy season.

          -  History of abnormal gastric or duodenal eosinophilia (e.g. HES, Churg Strauss
             vasculitis, EG or a parasitic infection)

          -  Receipt of forbidden prescribed or over the counter medication within the 4 weeks
             prior to the baseline visit and for the duration of the trial, including vitamins and
             herbal remedies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Straumann, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swiss EoE Research Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Swiss EoE Research Group</name>
      <address>
        <city>Olten</city>
        <zip>CH-4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2010</study_first_submitted>
  <study_first_submitted_qc>January 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2010</study_first_posted>
  <last_update_submitted>January 4, 2012</last_update_submitted>
  <last_update_submitted_qc>January 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EoE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indoleacetic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

